European Archives - Page 734 of 899 - European Medical Journal

Continue
23 Mins
22nd November 2016

Review of the European Society of Medical Oncology Congress 2016

This year, Copenhagen played host to the annual ESMO Congress which took place over 5 days and welcomed 20,522 participants. During the closing press…
November 2016

EMJ Oncology 4.1 2016

Welcome to this year’s edition of EMJ Oncology, a must-read for all those with a passion for oncology.
EMJ
4 Mins
22nd November 2016

Prize Winners at the ESMO Annual Meeting 2016

This year’s ESMO congress was hosted in the beautiful city of Copenhagen, Denmark. A city admired for being simultaneously traditional and modern, and…
2 Mins
22nd November 2016

Introducing EMJ Oncology 4.1

United Kingdom, November 15, 2016: Welcome to this year’s edition of EMJ Oncology, a must-read for all those with a passion for oncology.
9 Mins
22nd November 2016

State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers

This symposium provided an overview of the efficacy and safety of multikinase inhibitors in colorectal cancer, including treatment sequencing, followed…
10 Mins
22nd November 2016

Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma

Prof D’Amore opened the symposium by highlighting that management of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma…
2 Mins
22nd November 2016

Cabozantinib as First-Line Therapy for Patients with Metastatic Renal Cell Carcinoma with Poor or Intermediate-Risk Characteristics

The oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) sunitinib is a standard first-line therapy for patients with…
8 Mins
22nd November 2016

Regorafenib in Metastatic Colorectal Cancer and Advanced Soft Tissue Sarcomas

Oncologists face multiple challenges when treating patients with cancer, especially if patients are elderly or if they experience adverse events (AEs).
8 Mins
22nd November 2016

Editor’s Pick: Muscle Dysfunction in Childhood Cancer: Biological Mechanisms and Implications for Long-Term Survivorship

Paediatric cancer treatment has advanced significantly over the last half century to a point where >80% of all childhood cancer cases survive >5 years…
8 Mins
22nd November 2016

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML).